In conclusion, this study highlights the continuous evolution and potential of C14-PEI micelleplexes in advancing CRISPR-Cas9-based therapies for targeted genetic interventions, particularly in addressing mutations such as KRAS in cancer treatment. The gene discussed is KRAS; the disease is cancer.